111 Capital’s Iovance Biotherapeutics IOVA Stock Holding History

111 Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,809	Closed	-$20.3K	–	582
2025 Q2	$20.3K	Buy	+11,809	New	+$29.4K	﹤0.01%	496

Other funds holding IOVA

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

111 Capital's IOVA Position: Q3 2025 in Review

111 Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 11,809 shares — an estimated $20.3K sold.

111 Capital first reported a position in IOVA in Q2 2025 and held it in 1 quarter. The position peaked at $20.3K in Q2 2025. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

111 Capital reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 11,809 Iovance Biotherapeutics shares in Q3 2025, an estimated $20.3K.
111 Capital first reported a position in Iovance Biotherapeutics in Q2 2025 and held it in 1 quarter.
111 Capital's Iovance Biotherapeutics position peaked at $20.3K in Q2 2025.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.